Abstract:The p21-activated kinase 1 (PAK1), a serine/threonine kinase that orchestrates cytoskeletal remodeling and cell motility, has been shown to function as downstream node for various oncogenic signaling pathways to promote cell proliferation, regulate apoptosis and accelerate mitotic abnormalities, resulting in tumor formation and invasiveness. Although alterations in PAK1 expression and activity have been detected in various human malignancies, its potential biological and clinical significance in renal cell carcinoma (RCC) remains obscure. In this study, we found increased PAK1 and phosphorylated PAK1 levels in tumor tissues according to TNM stage progression. Elevated phosphorylated PAK1 levels associated with progressive features and indicated unfavorable overall survival (OS) as an independent adverse prognosticator for patients with RCC. Moreover, PAK1 kinase activation with constitutive active PAK1 mutant T423E promoted growth, colony formation, migration, invasion and stem-like phenotype of RCC cells, and vice versa, in PAK1 inhibition by PAK1 kinase inactivation with specific PAK1 shRNA, dead kinase PAK1 mutant K299R or allosteric inhibitor IPA3. Stem-like phenotype due to sunitinib administration via increased PAK1 kinase activation could be ameliorated by PAK1 shRNA, PAK1 mutant K299R and IPA3. Furthermore, nuclear factor-κB (NF-κB)/interleukin-6 (IL-6) activation was found to be responsible for PAK1-mediated stem-like phenotype following sunitinib treatment. Both IL-6 neutralizing antibody and IPA3 administration enhanced tumor growth inhibition effect of sunitinib treatment on RCC cells in vitro and in vivo. Our results unraveled that oncogenic activation of PAK1 defines an important mechanism for maintaining stem-like phenotype and sunitinib resistance through NF-κB/IL-6 activation in RCC, lending PAK1-mediated NF-κB/IL-6 activation considerable appeal as novel pharmacological therapeutic targets against sunitinib resistance.

P21-Activated Kinase 1 (PAK1) Can Promote ERK Activation in a Kinase-independent Manner

P21-activated Kinase 1 and Breast Cancer

P-21 Activated Kinases in Liver Disorders

P21-activated Protein Kinase 1 Induces Colorectal Cancer Metastasis Involving ERK Activation and Phosphorylation of FAK at Ser-910.

PAK is essential for RAS-induced upregulation of cyclin D1 during the G(1) to S transition

PAK1-dependent MAPK Pathway Activation is Required for Colorectal Cancer Cell Proliferation

Biology of the p21-Activated Kinases

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

PRL-1 Protein Promotes ERK1/2 and RhoA Protein Activation Through a Non-canonical Interaction with the Src Homology 3 Domain of P115 Rho GTPase-activating Protein*

Trihydrophobin 1 Interacts with PAK1 and Regulates ERK/MAPK Activation and Cell Migration*

I Kappa B Kinase Epsilon And Tank-Binding Kinase 1 Activate Akt By Direct Phosphorylation

Direct Interaction of P21-Activated Kinase 4 with PDZ-RhoGEF, a G Protein-linked Rho Guanine Exchange Factor*

Activating Mutations in MEK1 Enhance Homodimerization and Promote Tumorigenesis.

P-21 Activated Kinase 1 Knockdown Inhibits Β-Catenin Signalling and Blocks Colorectal Cancer Growth.

P21-activated Kinase 1 Promotes Colorectal Cancer Survival by Up-Regulation of Hypoxia-Inducible Factor-1Α

The phosphorylation of Pak1 by Erk1/2 for cell migration requires Arl4D acting as a scaffolding protein

PAK signaling in oncogenesis

The Activation of MEK1 by Enhanced Homodimerization Drives Tumorigenesis

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--opportunities, Challenges, and Limitations.

P21-Activated Kinase 1 Determines Stem-Like Phenotype and Sunitinib Resistance Via NF-κB/IL-6 Activation in Renal Cell Carcinoma

P21-Activated Protein Kinase 4 (pak4) Interacts with the Keratinocyte Growth Factor Receptor and Participates in Keratinocyte Growth Factor-Mediated Inhibition of Oxidant-Induced Cell Death